Announcements Trials
Browse Landscape

Phase

Phase 2 18Phase 1 16Phase 1/2 4Phase 3 1

Status

Completed 13Terminated 4Unknown 3Withdrawn 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 2Genitourinary 1Dermatologic 1

Conditions

Breast Neoplasms 2Neoplasm Metastasis 1Melanoma 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 75Carboplatin 61Cyclophosphamide 58Nivolumab 50Paclitaxel 47Gemcitabine 44Cisplatin 43Dexamethasone 41Radiotherapy 35Rituximab 32Capecitabine 31Docetaxel 29Bevacizumab 29fludarabine 27atezolizumab 26Cytarabine 26avelumab 24Trastuzumab 23Oxaliplatin 23Lenalidomide 23Cetuximab 23venetoclax 22Fluorouracil 22Azacitidine 22Temozolomide 21Ipilimumab 21130-nm albumin-bound paclitaxel 21fludarabine phosphate 20Filgrastim 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × Panobinostat × Clear all
NCT01582009 2022-08-15

Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate

Roswell Park Cancer Institute

Phase 1/2 Terminated
26 enrolled 11 charts
Genitourinary

Carcinoma, Renal Cell

NCT00925132 2017-07-02

Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat

University of Iowa

Phase 1/2 Terminated
39 enrolled 8 charts
Dermatologic

Melanoma, Neoplasm Metastasis

NCT00567879 2016-05-09

A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab

Novartis

Phase 1/2 Terminated
56 enrolled 5 charts
Breast

Breast Neoplasms

NCT01194908 2015-01-26

Re-expression of ER in Triple Negative Breast Cancers

Emory University

Phase 1/2 Terminated
5 enrolled 5 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡